Psyence Biomedical is developing botanical psilocybin-based psychedelic medicines aimed at treating anxiety and depression in palliative care settings. The company utilizes an evidence-based approach to create safe and effective therapeutics derived from natural sources, addressing the need for improved mental health solutions in terminally ill patients.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients in palliative care settings often experience significant anxiety and depression, which can be difficult to treat with existing pharmaceutical interventions. Current mental health solutions may not adequately address the unique needs and sensitivities of terminally ill patients.
Solution
Psyence Biomedical is developing botanical psilocybin-based medicines to address anxiety and depression in palliative care. The company focuses on creating safe and effective therapeutics derived from natural sources. Psyence Biomed utilizes an evidence-based approach, combining rigorous scientific research with nature-derived compounds. Their goal is to provide innovative solutions for mental health disorders, specifically targeting the unmet needs within palliative care. By focusing on botanical psilocybin, Psyence aims to offer a gentler, more holistic approach to managing mental health challenges in vulnerable patients.
Target Audience
The primary target audience includes patients in palliative care settings suffering from anxiety and depression, as well as healthcare providers specializing in palliative medicine and mental health.
Features
- Development of botanical (non-synthetic) psilocybin-based psychedelic medicines.
- Focus on mental health disorders, specifically anxiety and depression, in palliative care settings.
- Evidence-based approach to ensure safety and efficacy.
- Utilization of nature-derived compounds for therapeutic development.
- Clinical trial execution for mental health and neurological conditions.